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Background: In our previous study, we detected decreased expression of phospho-Smad1/5/8 and its upstream
signaling molecule, bone morphogenetic protein receptor IB subunit (BMPR-IB), in certain glioblastoma tissues,
unlike normal brain tissues. In order to clarify the functional roles and mechanism of BMPR-IB in the development
of glioblastoma, we studied the effects of BMPR-IB overexpression on glioblastoma cell lines in vitro and in vivo.
Methods: We selected glioblastoma cell lines U251, U87, SF763, which have different expression of BMPR-IB to be
the research subjects. Colony formation analysis and FACS were used to detect the effects of BMPR-IB on the
growth and proliferation of glioblastoma cells in vivo. Immunofluresence was used to detect the differentiation
changes after BMPR-IB overexpression or knocking-down. Then we used subcutaneous and intracranial tumor
models to study the effect of BMPR-IB on the growth and differentiation of glioblastoma cells in vivo. The genetic
alterations involved in this process were examined by real-time PCR and western blot analysis.ed.
Results and conclusion: Forced BMPR-IB expression in malignant human glioma cells, which exhibit lower
expression of BMPR-IB, induced the phosphorylation and nuclear localization of smad1/5/8 and arrested the cell
cycle in G1. Additionally, BMPR-IB overexpression could suppress anchorage-independent growth and promote
differentiation of theses glioblastoma cells. Furthermore, overexpression of BMPR-IB inhibited the growth of
subcutaneous and intracranial tumor xenografts and prolonged the survival of mice injected intracranially with
BMPR-IB-overexpressing glioblastoma cells. Conversely, inhibition of BMPR-IB caused SF763 malignant glioma cells, a
line known to exhibit high BMPR-IB expression that does not form tumors when used for xenografts, to show
increased growth and regain tumorigenicity in a nude mouse model system, ultimately shortening the survival of
these mice. We also observed significant accumulation of p21 and p27kip1 proteins in response to BMPR-IB
overexpression. Our study suggests that overexpression of BMPR-IB may arrest and induce the differentiation of
glioblastoma cells due to upregulation of p21 and p27kip1 in vitro and that in vivo and decreased expression of
BMPR-IB in human glioblastoma cells contributes to glioma tumorigenicity. BMPR-IB could represent a new
potential therapeutic target for malignant human gliomas.
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Malignant gliomas are the most common primary tumors
in the brain; they are destructive, invasive, and the most
highly vascularized lethal tumors observed in humans.
Gliomas are classified into grades I – IV according to their
histological degree of malignancy by the WHO criterion.
Despite recent progress in combination therapies, the me-
dian survival of patients with glioblastoma (WHO grade
IV) is less than 14–15 months [1]. Advances in the treat-
ment of malignant gliomas will require improved under-
standing of the biology and molecular mechanisms of
glioma development and progression. Many studies show
that the malignant transformation of glioma is a conse-
quence of the stepwise accumulation of genetic alterations
that lead to aberrant regulation of proliferation and differ-
entiation signals and disruption of the apoptotic pathway
[1]. Recent research on the molecular basis of gliomas and
the implications for targeted therapeutics has focused on
the PTEN, EGFR and VEGF signaling pathways [2-4].
These pathways, while important, represent only a subset
of the multiple molecular mediators of glioma tumorigen-
esis and malignancy [1].
A previous study by our group showed that the ex-
pression of bone morphogenetic protein receptor IB
subunit (BMPR-IB) is decreased in most malignant
human glioma tissues, including anaplastic astrocytomas
and glioblastomas. Furthermore, the low expression of
BMPR-IB was found to contribute to a lower ratio of
phospho-Smad1/5/8 to Smad1/5/8 expression, which
correlates significantly with poor patient survival [5].
Thus, it would not be unreasonable to speculate that
BMP signals may participate in the development and
progression of gliomas.
BMPs are the subclass of the transforming growth fac-
tor-β (TGF-β) superfamily, including more than 20 mem-
bers. BMP ligands and receptor subunits are present
throughout neural development and mediate a diverse
array of developmental processes, including cellular sur-
vival, proliferation, morphogenesis, lineage commitment,
differentiation and apoptosis of neural stem cells in the
CNS [6-8]. Additionally, during regional and cellular
maturation, BMPs can mediate long-range signaling by
acting as gradient morphogens, or they can mediate
short-range signaling by modulating cell-cell communi-
cation [6,7,9]. BMP signals transduce intracellular signals
through type I (BMP-RIA and BMP-RIB) and type II
(BMP-RII) serine/threonine kinase receptors. Binding of
BMPs to BMPR-II results in phosphorylation of BMPR-I
and downstream Smad proteins. BMPs activate Smad1/
5/8, which can associate with Smad4 in a heterodimeric
complex upon phosphorylation that is translocated to
the nucleus, where it activates transcription [10-13].
Although the BMP pathways have emerged as import-
ant contributors to many human neoplastic conditions[14,15], the role of BMPs/BMPRs in human glioma has
not been completely defined. In the present study, we
continued to investigate how BMPR-IB regulates the
growth of glioblastomas.
Methods
Cell lines and cell culture
The human malignant glioma cell lines SF126, SF763,
and M17 were obtained from the American Type Cul-
ture Collection. The glioblastoma cell line U-251 and
normal human astrocytes, which were described previ-
ously (5), were also used. These cell lines were cultured
in D/F12 medium supplemented with 10% fetal bovine
serum (FBS), (Hyclone USA).
Animals
The athymic BALB/c nude mice (female), which weight
from 25 to 28 g, were purchased from the Animal Cen-
ter of the Chinese Academy of Medical Science. The
mice were bred in laminar flow cabinets under specific
pathogen-free conditions and handled according to the
policies and standards of Laboratory Animal Care in
China.
Stable transfection of glioma cells
To generate a recombinant AAV serotype 2 –BMPR-IB
(rAAV2-BMPR-IB) viral vector, full-length cDNA for
human BMPR-IB was obtained by EcoRI and BamH1 di-
gestion and subcloned into the pSNAV plasmid (Invitro-
gen) and was then recombined into rAAV2. U87 and
U251MG cells were infected with AAV-BMPR-IB or con-
trol virus to generate BMPR-IB-overexpressing glioblast-
oma cells. To generate a BMPR-IB small interfering
RNA (siRNA) expression vector for gene knockdown
studies, four BMPR-IB siRNAs were designed and
synthesized (Invitrogen, USA). A siRNA with the se-
quence 5′-GGACCCAGUUGUACCUAAUdTdT-3′ was
determined to be the most effective siRNA for inhibiting
BMPR-IB expression. The BMPR-IB siRNA was further
incorporated into the pSilencer plasmid (Ambion, USA).
SF763 cells were transfected with the BMPR-IB siRNA
expression vector (si-BMPR-IB) or the control vector (si-
control). The cell lines, which stably expressed BMPR-IB
siRNA, were isolated by neomycin (G418) selection.
Quantitative real-time RT-PCR
Total RNA, which derived from glioma cells, was pre-
pared using TRIzol (Gibco), and further purified using
the RNeasy Mini Kit (Qiagen). Real-time PCR was per-
formed according to the manufacturer’s instructions
using an ABI Prism 7900 sequence detection system
(Applied Biosystems, USA). Primers and probes for p21,
p27, p53, CDK2, CDK4, Skp2, BMPR-IB (human) and
GAPDH were obtained from Applied Biosystems, USA.
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primer sequences of theses genes. All samples were
tested in triplicate. The relative number of target tran-
scripts was normalized to the number of human
GAPDH transcripts in the same sample. The relative
quantitation of target gene expression was performed
using the standard curve or comparative cycle threshold
(Ct) method.
Western blot analysis
Whole-cell lysates were isolated from glioma cells and
the transplanted glioma tissues (5). Standard western
blotting was performed with monoclonal antibodies
against human BMPR-IB, p21, p27KIP1, Skp2, Cdk2,
Cdk4, p53, GFAP, Nestin and β-actin proteins(Santa
Cruz Biotechnology,USA) and the corresponding sec-
ondary antibodies (anti-rabbit IgG, anti-mouse IgG, and
anti-goat IgG; Abcam, USA). Human β-actin was used
as a loading control. These proteins were detected using
the Amersham enhanced chemiluminescence system
according to the manufacturer’s instructions.
Immunofluorescent staining
At 48 h following AAV-BMPR-IB infection, the U251 and
U87 cells were fixed in 4% paraformaldehyde-PBS. After
incubation with 0.1% Triton-PBS for 30 min and blocking
with 1% bovine serum albumin-PBS for 2 h in room
temperature, the cells were then incubated with the pri-
mary antibodies overnight in 4°C at the concentration
recommended by the supplier (a rabbit anti-phospho-
Smad1/5/8 antibody (Cell signal), a goat anti-BMPR-IB
antibody (Santa Cruz Biotechnology) and a mouse anti-
GFAP antibody (Sigma)). After washing with 0.1% Triton-
PBS three times, cells were incubated with RBITC-conjugated
rabbit anti-goat IgG and FITC-conjugated goat anti-
rabbit IgG (Santa Cruz Biotechnology) for 2 h in room
temperature. The cell nuclei were stained with DAPI.
The stained cells were visualized and mounted with a
confocal laser scanning microscope (Olympus).
Analysis of cell cycle distribution
Glioma cells were harveseted and washed with 1×PBS
three times, then fixed by 70% Ethanol for 1 h. Ethanol-
fixed cells were treated with RNase (10 mg/ml in PBS)
and stained with propidium iodide (100 μg/mL in PBS)
for 30 min at 37°C. Stained cells were tranfered to FACS
tubes and detected using flow cytometry (Becton Dickin-
son Immunocytometry Systems, San Jose, CA).
Colony formation in soft agar
U87 and U251 cells were infected with either rAAV2-
BMPR-IB or the control vector rAAV2, SF763 cells were
stably transfected with the BMPR-IB siRNA oligonucleo-
tide or control siRNA. After 48 h of infection, cells weretrypsinized, and 2×104 cells were mixed with a 0.5% agar
solution in DMEM/F12 containing 10% FBS and 200 μg/mL
neomycin, then layered on top of 0.70% agar in 35 mm
culture plates. The plates were incubated at 37°C in a
humidified incubator for 10–14 days. Colonies were then
stained with 0.005% Crystal violet for 1 h, and counted
using a dissecting microscopically in 8 randomly chosen
microscope fields. Only colonies containing >50 cells
were scored.Subcutaneous tumor growth
To study the kinetics of glioma cells growth in vivo, gli-
oma cells (3 × 106 or 1 × 107 cells in 50 μl of PBS) were
injected s.c. into the right armpit of nude mice. The
diameter of the resulting tumors was measured once
every 5 days. The ability of tumor formation was deter-
mined by measurement of the diameters of subcutane-
ous tumors.Intracranial human glioma xenograft model
Glioma cells (1 × 106/4μl) were grown in metrigel for
2 h, then implanted into the right striatum of nude mice
by stereotactic injection (0.2 μl/min). The injection coor-
dinates were: anteroposterior = 0; mediolateral = 3.0 mm;
and dorsoventral = 4.0 mm. Animals showing general or
local symptoms were killed; the remaining animals were
killed 90 days after glioma cell injection by perfusion of
4% formaldehyde. The brain of each mouse was har-
vested, fixed in 4% formaldehyde, and embedded in par-
affin. Tumor formation and phenotype were determined
by histological analysis of hematoxylin and eosin (H&E)-
stained sections. Two independent experiments were
performed, with five mice per group in each experiment.Histology and immunohistochemistry of xenograft
tumors
Fixed Brain tissue specimens were embedded in paraffin,
sectioned, and stained with H&E according to standard
protocols. Tissue sections were immunostained using
mouse anti- GFAP and goat anti-CD34 monoclonal
antibodies (Santa Cruz Biotechnology,USA) to detect
the growth, differentiation and angiogenesis of the
xenografts.Statistics
All of the values were calculated as mean±SE. Student’s
t-test was used to analysis the significance of the results
in vitro, whereas the significance of the results in vivo
was determined by the Mann–Whitney U test. Kaplan–
Meier survival analysis was used to analysis the overall
survival times of the glioblastoma nude mouse.
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Expression of members of the BMPs/Smad1/5/8 signaling
pathway in different malignant glioma cell lines
We examined the mRNA and protein expressions of
BMP2, BMPR-II, BMPR-IA, BMPR-IB and Smad1/5/8
in normal astrocytes and malignant glioma cell lines
using real-time RT-PCR and western blot analysis, re-
spectively. We found that the mRNA expression of
BMPR-IB mRNA in all glioblastoma cell lines decreased
compared to normal astrocytes, while the expression of
the other genes remained similar between normal astro-
cytes and malignant glioma cell lines (Figure 1A). Fur-
thermore, the protein expression of BMPR-IB and
phospho-Smad1/5/8 in all malignant glioma cell linesFigure 1 Determination of BMPR-IB expression in normal human astr
determine the mRNA expressions of BMPR-IB and other factors involved in
employed to show the protein expression of BMPR-IB, P-Smad1/5/8 and Sm
from WB analysis(down). (C) Alterations in the expression of BMPR-IB and P
analysis. (D) Immunofluorescence analysis of the activation of Smad1/5/8 awas lower than the levels in normal astrocytes; intracel-
lular protein expression of BMPR-IB was moderately
lower in SF763 cells and drastically lower in other ma-
lignant glioma cell lines compared to normal astrocytes
(Figure 1B). We overexpressed BMPR-IB in U87 and
U251 cells following rAAV infection. Forty-eight hours
after infection, a significant increase of BMPR-IB and
phospho-smad1/5/8 protein expression was confirmed
in the rAAV-BMPR-IB-infected U87 and U251 cell lines
by western blot analysis (Figure 1C). Furthermore, im-
munofluorescent staining with an anti-phospho-smad1/
5/8-specific antibody showed nuclear translocation of
phospho-smad1/5/8 after 48 h of AAV-BMPR-IB infec-
tion (Figure 1D).ocytes and glioma cell lines. (A) Real-time-RT-PCR was used to
BMP/BMPR signaling pathway. (B) Western blot analyses were
ad1/5/8 in glioblastoma cell lines(up). Statistical analysis of results
-Smad1/5/8 after 48 h of BMPR-IB overexpression, determined by WB
fter 48 h of BMPR-IB infection.
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the cell cycle progression of glioblastoma cells
We overexpressed BMPR-IB with rAAV in U87 and
U251 cells and suppressed BMPR-IB expression in
SF763 cells with siBMPR-IB. Forty-eight hours after in-
fection and transfection, a significant increase in BMPR-
IB protein expression in the rAAV-BMPR-IB-infected
U87 and U251 cell lines and a decrease in BMPR-IB pro-
tein expression in the BMPR-IB siRNA-transfected
SF763 cell line were confirmed by western blot analysis
(Figure 2A). Defects in the regulation of cell cycle pro-
gression are thought to be among the most common
features of glioblastoma multiforme [1]. Therefore, we
used flow cytometry to assess whether BMPR-IB expres-
sion could affect the cell cycle progression of glioblast-
oma cells. As shown in Figure 2B, the percentage of
BMPR-IB-infected U87 and U251 cells in G1/G0 phase
was higher compared to that of control vector rAAV-
infected cells. Conversely, the percentage of si-BMPR-IB
transfected SF763 cells in G0/G1 phase was lower rela-
tive to that of si-control-transfected SF763 cells.Effects of BMPR-IB overexpression and knock-down on
the growth of glioblastoma cells in vitro
After 5 days of BMPR-IB overexpression or knock-down,
the anchorage-independent growth of BMPR-IB-overex-
pressing glioblastoma cells was drastically inhibited, as
shown by a decrease in the number and volume of col-
onies on soft agar compared with control cells, and the
anchorage-independent growth of SF763 cells treated
with siBMPR-IB was 2 times as high as that of the si-Figure 2 Effects of altered BMPR-IB expression on the cell cycle of hu
expression in parental glioma cells, control vector–AAV and AAV-BMPR-IB-in
expressed as the mean±SD, n = 3. *, P< 0.05).control-treated cells. BMPR-IB overexpression decreased
the colony numbers of U251 and U87 by 55% and 66%,
and BMPR-IB knock-down caused an approximate 94%
increase in colony numbers compared with controls
(Figure 3A, B).Effects of BMPR-IB overexpression and knock-down on
the differentiation of glioblastoma cells in vitro
The contrast photomicrographs showed that the glio-
blastoma cell lines U87 and U251 were prone to differ-
entiate after 2 days of rAAV-BMPR-IB infection.
Conversely, BMPR-IB knock-down inhibited the out-
growth of neurites in SF763 cells (Figure 4A). Immuno-
fluorescence analysis showed that BMPR-IB infection
increased the expression of GFAP protein, which is a
recognized marker of astrocytic differentiation, whereas
BMPR-IB knock-down decreased the expression of
GFAP protein (Figure 4A). Further investigation using
western blot analysis showed that BMPR-IB overexpres-
sion increased the expression of GFAP protein and
inhibited the expression of Nestin, which is a marker of
CNS precursor cells. In addition, BMPR-IB knock-down
decreased the expression of GFAP protein and increased
the expression of Nestin protein (Figure 4B).Effects of altered BMPR-IB expression on the mRNA and
protein levels of Skp2, p21, p27Kip1, Cdk2, Cdk4 and p53
in glioma cell lines
To identify the mechanisms related to the growth inhib-
ition and differentiation of glioma cells secondary to
BMPR-IB overexpression, we first examined the mRNAman glioblastoma cells. (A) Western blot analysis of BMPR-IB
fected cells. (B) Cell cycle distribution analysis histogram. (Values are
Figure 3 Determination of anchorage-independent growth of human glioma cells with altered BMPR-IB expression using a soft-agar
colony formation assay. (A) Microphotographs of colonies. (B) Columns, the mean of the colony numbers on triplicate plates from a
representative experiment (conducted twice); bars, SD. *, P< 0.001, as determined using Student’s t-test.
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ing p21, p27Kip1, Skp2, Cdk2, Cdk4 and p53, by real-
time RT-PCR and found increased expression of p21,
p27, and Cdk2 mRNA, decreased expression of Skp2
mRNA, and consistent expression of p53 mRNA after
96 h of BMPR-IB infection of U87 and U251 cells
(Figure 5A). We further examined whether BMPR-IB
influences the protein expression of p21, p27Kip1, Skp2
and p53 by western blot analysis. We found a significant
increase in the expression levels of the p21 and p27 pro-
teins. The level of expression of the Skp2 protein, which
is the specific recognition factor for p27Kip1 ubiquitina-
tion, was significantly lower in rAAV-BMPR-IB infected
U87 and U251 cells compared with controls. Conversely,
knock-down of BMPR-IB decreased the protein expres-
sion of p21 and p27 and increased the protein expression
of Skp2. Additionally, Cdk2 and p53 proteins showed no
significant changes in response to the alterations of the
expression of BMPR-IB (Figure 5B).
The effects of BMPR-IB overexpression and knock-down
on the tumorigenicity of human glioblastoma cells in vivo
Additionally, we studied the kinetics of glioma cell
growth using a subcutaneous xenograft and an intracra-
nial xenograft in the nude mouse model system. As
shown in Figure 6A, primary U251 cells and control vec-
tor-rAAV infected U251 (U251-AAV) cells (3× 106 per
mouse) formed aggressive, rapidly growing tumors that
reached a diameter of ≥ 8 mm within 40 days after
tumor cell injection. In contrast, U251-AAV-IB cells(3×106 per mouse) formed tiny masses (≤ 4 mm in
diameter) in nude mice by day 5 after injection. How-
ever, these masses shrank and disappeared within
25 days. The masses did not grow back over the follow-
ing 4 weeks (Additional file 1: Figure S3); thus, the for-
mation of these masses could have been the result of an
inflammatory reaction to the tumor cell injections. Con-
versely, inhibition of BMPR-IB caused malignant SF763
glioma cells to exhibit increased growth and regain tu-
morigenicity in the nude mouse model system (Figure 6A,
Additional file 1: Figure S3).
Next, to study the growth of these glioma cells in the
brain, we used a xenograft model of human glioma, in
which we injected glioma cells intracranially into nude
mice. As with the subcutaneously injected cells, intracra-
nially injected U251-AAV cells (1×107 per mouse)
formed invasive brain tumors that presented characteris-
tic glioblastoma features, including nuclear pleomorph-
ism, prominent mitotic activity, and highly invasive
behavior (Figure 6B). These tumor masses also exhibited
microvascular proliferation characterized by a substan-
tially increased number of CD34-positive microvessels
(Additional file 1: Figure S4). Intracranial injection of
U251-AAV-IB cells (1× 107 per mouse) did not result in
the formation of invasive tumors; instead, small, delim-
ited lesions confined to the injection site were observed
90 days after injection. Immunohistology showed that
these tumor masses presented a more mature morph-
ology than that in control groups, characterized by the
increased expression of GFAP, and less ventricular
Figure 4 Induction of differentiation by BMPR-IB in human glioma cell lines. (A) After infection and transfection with rAAV-BMPR-IB and si-
BMPR-IB, the expression of GFAP of glioblastoma cells was detected by immunofluorescence (left), and the morphological alterations were
examined by phase contrast microscope(right). (B) WB analysis showed that BMPR-IB infection induced the expression of endogenous GFAP and
inhibited the expression of Nestin, whereas BMPR-IB knock-down decreased the expression of GFAP and increased the expression of Nestin.
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showed that BMPR-IB overexpression significantly
extended the survival time of the mice compared with
the controls (P< 0.0001; Figure 6B, C). Conversely,
SF763 si-control infected cells did not produce tumors
intracalvarially in injected mice; however, the SF763-
Si-BMPR-IB cells produced invasive brain tumors intra-
calvarially, which resulted in decreased overall survival
time compared with controls (P< 0.0001, Figure 6B, C).
Discussion
Although several studies have suggested that BMPR-IB
plays an important role in the development of some
solid tumors, such as prostate cancer and breast cancer
[14,15], its role and associated molecular mechanisms
related to the development of glioma are not completely
understood. In our study, we found both clinical andexperimental evidence that aberrant BMPR-IB expres-
sion critically regulates the tumorigenicity of human gli-
oma cells in vitro and in vivo [5]. We also provided the
first evidence that BMPR-IB inhibits the growth of glio-
blastoma cells and promotes their differentiation by
regulating the gene expression of p21, p27Kip1 and
Skp2, which plays important roles in cell cycle
regulation.
Previously, in clinical glioma specimens, we found
decreased expression of BMPR-IB mRNA and protein in
malignant glioma tissues compared to the levels in nor-
mal brain tissues and benign glioma tissues, whereas the
expression of other molecules in the signaling pathway
of BMPs/Smad1/5/8 remained consistent. We also found
an inverse correlation between the protein and mRNA
expression levels of BMPR-IB and malignancy grade [5].
From these clinical results, we assumed that BMPR-IB
Figure 5 Effects of altered BMPR-IB expression on the mRNA and protein expression of p21, CDK2, CDK4, p27Kip1, Skp2 and p53 in
human glioma cell lines. (A) Real-time RT-PCR was used to reveal alterations in the mRNA expression of p21, CDK2, CDK4, p27Kip1, Skp2 and
p53 (values are expressed as the mean ± SD, n = 3. *, P< 0.05). (B) Western blot analysis showed alterations in the protein expression of p21,
p27Kip1, Skp2 and p53 in these cell lines. Equal protein loading was monitored by hybridizing the same filter membrane with anti-beta-actin
antibodies. (C) Statistical analysis of results from WB analysis. (Values are expressed as the mean ± SD, n = 3. *, P< 0.05).
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our present study, we selected several malignant human
glioblastoma cell lines that have different expressions of
BMPR-IB to study the functional role of BMPR-IB in the
development of glioma. Because the malignant human
glioma cell lines that we selected have different expres-
sion levels of BMPR-IB, they are suitable as subjects for
the study of the functional roles of BMPR-IB in vitro.
Hyperproliferation is a hallmark of glioblastoma multi-
forme. Our present study showed that BMPR-IB overex-
pression decreased the anchorage-independent growth
of U87 and U251 glioblastoma cells, which present a
lower expression of BMPR-IB in vitro. Further, the
reduced BMPR-IB expression caused an increase in the
number of SF763 colonies that express higher levels of
BMPR-IB compared to other glioma cell lines. Addition-
ally, FACS analysis showed that this effect was at least
partially caused by the inhibition of glioma cell cycle
progression at the G0/G1 transition (Figure 2B, 3B).
These data suggest that BMPR-IB protein plays an in-
hibitory role in the development of glioblastoma and
might be a key regulator of the G1-S transition in glio-
blastoma cells. A recent study by Piccirillo et al. has also
shown that BMP4 may act as a key inhibitory regulator
of tumor-initiating, stem-like CD133+ cells from GBMs.
However, those authors did not address the aberrant ex-
pression of BMPR-IB in the primary tumor-initiating
cells that were derived from GBM tissues [16]. Wedetected the expression of CD133 in U251/U87/SF763
cell lines, and found that most of these cells were
CD133- (Additional file 1: Figure S2). So, the tumor
inhibited effects of BMPR-IB in our study are on those
glioblstoma cells that express a low level of BMPR-IB,
but are not limited to the fraction of cells with a stem
cell-like phenotype (CD133+ cells) as reported by Pic-
cirllo. et al.
It has been reported that BMP2/4 acts as a neuroepi-
thelial proliferation signal at very early stages of embry-
onic central nervous system development, an effect
mediated principally by BMPR1A [17,18]. Later in the
development of the central nervous system, BMP2/4
induces neuronal and astrocytic differentiation of NSCs,
an event that coincides with increased expression of
BMPR1B [19,20]. Another study by Lee et al. has shown
that BMPR-IB was able to induce the differentiation of
a kind of gliomblastoma initiated cell [21]. In accord-
ance with their findings, our present results suggest
that human glioblastoma cell lines retain the BMPR-
IB-mediated, signaling pathway that is responsible for
growth arrest and astrocytic differentiation. Thus, our
studies, together with their findings, should provide
an attractive therapeutic strategy for the treatment of
glioblastoma.
Although, Lee et al. also reported that BMPR-IB could
induce the differentiation of a kind of gliomblastoma
initiated cell, they did not clarify the signaling pathway
Figure 6 (See legend on next page.)
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Figure 6 Overexpression of BMPR-IB in human glioma cells decreased tumorigenicity in vivo. (A) Tumor growth in the subcutis of nude
mice. (B) Representative H&E staining and immunohistochemistry of tumors derived from intracranial xenografts of glioma cells.aL-dL(low
magnification images)L and a-d(high magnification images), HE staining of tumors derived from intracranial xenografts of glioma cells. e-h, GFAP
immunohistocheistry of tumors derived from intracranial xenografts of glioma cells. i-l, CD34 immunohistocheistry of tumors derived from
intracranial xenografts of glioma cells. (a, e, i, U251-AAV. b, f, j, U251-AAV-IB. c, g, k, SF763-si-control. d, h, l, SF763-si-IB). Magnification was ×20 in
a-d, and ×40 in e-l. (C) Survival of animals intracranially injected with glioma cells that were infected or knocked down using BMPR-IB and control
vectors (log rank test: p< 0.0001).
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we found that transient overexpression of BMPR-IB
could induce the phosphorylation and nuclear transloca-
tion of Smad1/5/8, which is the signaling molecule im-
mediately downstream from BMPR-IB [5]. However, the
detailed mechanism underlying the involvement of
BMPR-IB in the growth inhibition and differentiation of
glioblastoma remain indistinct. In the present study, we
provide the first evidence to show that the selective in-
duction of the key Cdk inhibitors (p27 Kip1 and p21) is
associated with this growth arrest and differentiation
processes.
The p27Kip1 is a potent tumor suppressor gene and
an inhibitor of the cell cycle [22]. P27Kip1 plays its sup-
pressive role through kinase-cyclin complexes that in-
hibit the phosphorylation of Rb that, in turn, results in
the arrest of cells at the G1 phase. Deregulated expres-
sion of p27Kip1 plays a critical role in the pathogenesis
of many human tumors. However, mutations of the
p27Kip1 gene seem to be extremely rare in human ma-
lignancies [23]. Several studies have shown that nuclear
expression of p27Kip1 decreases with malignancy in
human astrocytic gliomas and that p27Kip1 has an inde-
pendent prognostic value in patients who have malig-
nant glioma [24,25]. Recently, Skp2 was shown to
mediate the ubiquitin-mediated degradation of p27Kip1
as a specific substrate-recognition subunit and to have
oncogenic properties [26]. The study of Schiffer et al.
showed that the Skp2 expression level is directly corre-
lated with glioma grade, but inversely correlated with
the p27Kip1 level [27]. In this study, we also observed
that BMPR-IB overexpression up regulated the mRNA
and protein expressions of p21 and p27Kip1and
decreased the mRNA and protein expressions of Skp2.
The protein expression of p53, which is important in cell
cycle progression and apoptosis in tumors, remained
constant in these glioblastoma cell lines, regardless of
BMPR-IB infection (Figure 5). Thus, the molecular
mechanisms by which BMPR-IB induces the growth ar-
rest and differentiation of glioma cells are associated
with upregulation of the cell cycle kinase inhibitors p21
and p27Kip1, but not p53. Finally, p27Kip1 has been
shown to modulate apoptosis in various types of cells,
including glioblastoma multiforme cells [28,29]. In
addition, in our previous study [5], we also observedearly apoptosis in the glioblastoma cells, after transient
transfection of BMPR-IB for 48 h. Because apoptosis is a
large and important problem and thus we would con-
tinue to study the apoptotic effect and the mechanisms
in the future clearly and in detail.
Based on these findings, we inferred that the growth
arrest and differentiation of glioblastoma cells induced
by BMPR-IB overexpression in vitro might correspond
to a similar decline in the ability of rAAV-BMPR-IB
infected cells to form tumors in vivo. This supposition
was validated by our nude models of glioblastoma
xenografts. All animals that received U251-AAV cells
developed subcutaneous and intracranial tumor masses
(Figure 6A, B). These masses showed characteristic
glioblastoma features, including atypical nuclei, expres-
sion of aberrant glia and extensive neovascularization
(Figure 6B). Conversely, U251-AAV-IB cells did not
form invasive tumors(Figure 6A, B). Instead, rather,
small, delimited lesions were observed, which were con-
fined to the injection site. These tumors exhibited a
more mature morphology (Figure 6B). Kaplan–Meier
survival analysis showed that, after three to four
months of post-intracalvarial injection, most of the con-
trol animals died, whereas nearly all of the mice that
received rAAV-BMPR-IB infected cells survived (Figure 6C).
Furthermore, BMPR-IB siRNA transfected SF763 cells
showed reduced expression of BMPR-IB and re-
gained tumorigenicity in most of the injected mice
(Figure 6A, B, C). Thus, these results imply that BMPR-
IB may play a role in glioma progression in vitro and
in vivo.
In summary, our results show that overexpression of
BMPR-IB clearly inhibited the growth, and promoted
the differentiation, of glioma cells in vitro. In an animal
model system, overexpression of BMPR-IB significantly
inhibited the tumorigenicity of glioblastoma cells,
whereas reduced expression of BMPR-IB significantly
enhanced the tumorigenicity of these glioblastoma cells.
Importantly, overexpression of BMPR-IB activated the
BMPs/Smad1/5/8 signaling pathway and clearly inhib-
ited the growth of glioma cells through multiple
mechanisms, including decreased expression of Skp2,
and subsequently increased the expression of the p21
and p27Kip1 proteins. Our results imply that BMPR-IB
may play an inhibitory role in glioma progression, and
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Additional file
Additional file 1: Figure S1. The efficiency of AAV infection to U251
and U87 cells. U251 and U87 cells were infected with AAV vectors for
48 h, and then photographed using fluorescence microscope. Figure S2.
The expression of CD133 in glioblastoma cell lines and brain tumor stem
cells (BTSCs). Immunofluorescence was used to detect the expression of
CD133 in U251, U87, and SF763 glioblastoma cell lines and the
neurospheres of BTSCs. Figure S3. BMPR-IB inhibited the subcutaneous
growth of glioblastoma cells. A) The subcutaneous models of nude
glioblastoma cells, which over-expressed of BMPR-IB and knocked down
BMPR-IB. B) The tumor masses derived from the subcutaneous xenograft.
C) H&E staining of tumors derived from subcutaneous xenografts of
glioblastoma cells. N: Normal connective tissue; T: Glioblastoma tissue.
Figure S4. Quantitative analysis of CD34 positive microvessels in the
glioblastoma specimens. Glioblastoma specimens that were derived from
U251-C/U251-IB and SF763-si-Con/SF763-si-IB cells were stained by CD34
using immunohistochemistry method. Error bars represent SD (performed
in triplicate). *p< 0.01. Table S1. Primer sequences for p21, p27, p53,
CDK2, CDK4, Skp2, BMPR-IB (human) and GAPDH.
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